Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'
September 24, 2024 2:18 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We spoke with Regeneron (REGN, Buy) mgmt today who noted that they have appealed the court's decision as of last night, and... More
Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
September 24, 2024 5:30 AM EDTBaird analyst Brian Skorney reiterated a Neutral rating and $940.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "Incrementally negative on legal update. Regeneron's court battles to protect their 2mg Eylea from biosimilar competition has taken a surprising turn as... More
Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)
September 24, 2024 5:28 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $1,292.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We hosted an investor dinner with Len Schleifer, Co-Founder and CEO, and Ryan Crowe, SVP, IR & Strategic Analysis. They emphasized pipeline opportunities stemming from REGN's science-first approach, including: 1) Ph2 proof-of-concept data for the Factor XI antibody in thrombosis by YE, noting validation per genetic data; 2) Ph1 linvoseltamab+Dupixent data in severe food allergy by YE,... More
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
September 23, 2024 4:00 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,300.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "With today's denial of Regeneron's motion for a preliminary injunction, it's important that we take a step back and highlight the differences in product formulation across Eylea and select biosimilars as it remains unclear how these differences could contribute to differential rulings in the courtroom. Recall, Regeneron received a permanent injunction vs. Mylan back in June.... More
Truist Securities on Regeneron Pharma (REGN): 'view the pressure on stock as an overreaction'
September 23, 2024 3:40 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Regeneron (REGN, Buy) shares were down ~5% (vs. XBI down 2%) in reaction to a Judge denying REGN's preliminary injunction against Amgen's (AMGN, Buy)... More
